WANBURY

Wanbury Share Price

 

 

Start SIP in WANBURY

Start SIP

Performance

  • Low
  • ₹233
  • High
  • ₹239
  • 52 Week Low
  • ₹154
  • 52 Week High
  • ₹330
  • Open Price₹235
  • Previous Close₹237
  • Volume24,606

Investment Returns

  • Over 1 Month + 3.04%
  • Over 3 Month -4.81%
  • Over 6 Month -14.32%
  • Over 1 Year -11.81%

Smart Investing Starts Here Start SIP with Wanbury for Steady Growth!

Invest Now

Wanbury Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 16.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 833
  • P/B Ratio
  • 7.8
  • Average True Range
  • 9.86
  • EPS
  • 12.32
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.78
  • RSI
  • 50.35
  • MFI
  • 35.51

Wanbury Financials

Wanbury Technicals

EMA & SMA

Current Price
₹238.70
+ 1.75 (0.74%)
pointer
  • Bearish Moving Average 8
  • Bullish Moving Average 8
  • 20 Day
  • ₹237.07
  • 50 Day
  • ₹242.33
  • 100 Day
  • ₹248.52
  • 200 Day
  • ₹248.75

Resistance and Support

237.08 Pivot Speed
  • R3 247.42
  • R2 243.43
  • R1 241.07
  • S1 234.72
  • S2 230.73
  • S3 228.37

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Wanbury manufactures and markets pharmaceutical products, focusing on active pharmaceutical ingredients (APIs) and formulations. The company serves global markets with a range of therapeutic solutions in areas like anti-diabetics, pain management, and gastrointestinal treatments.

Wanbury has an operating revenue of Rs. 628.69 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 5% is okay, ROE of 51% is exceptional. The company has a high debt to equity of 270%, which can be a reason to worry. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 73 which is a FAIR score but needs to improve its earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 52 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has remained stable in the last reported quarter. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Wanbury Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-13 Quarterly Results
2025-08-04 Quarterly Results
2025-05-15 Audited Results
2025-02-12 Quarterly Results & Others Inter-alia, to consider 1. The issue of senior, secured, unlisted redeemable and non- convertible debentures on private placement basis and other matters in relation to such issue.
2024-11-13 Quarterly Results

Wanbury F&O

Wanbury Shareholding Pattern

39.63%
0%
0.8%
0%
43.84%
15.73%

Wanbury FAQs

Wanbury share price is ₹238 As on 26 December, 2025 | 02:40

The Market Cap of Wanbury is ₹832.9 Cr As on 26 December, 2025 | 02:40

The P/E ratio of Wanbury is 16.6 As on 26 December, 2025 | 02:40

The PB ratio of Wanbury is 7.8 As on 26 December, 2025 | 02:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23